78 citations
,
December 2008 in “The Journal of Sexual Medicine” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
Combining pentoxifylline with corticosteroids improves alopecia areata treatment.
40 citations
,
April 2018 in “Endocrine” PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.
7 citations
,
July 2020 in “Pigment cell & melanoma research” RT1640 treatment reverses gray hair and promotes hair growth in mice.
May 2021 in “Zenodo (CERN European Organization for Nuclear Research)”
33 citations
,
October 2016 in “European Journal of Pharmaceutical Sciences” Effervescent formulations may improve minoxidil delivery, increasing effectiveness and reducing applications needed.
May 2022 in “Endocrine Abstracts” Finasteride may cause sexual dysfunction by reducing epinephrine levels.
March 2023 in “International Journal of Applied Pharmaceutics” The β-sitosterol hair gel is effective and promising for treating hair loss.
November 2025 in “The Bioscan.” Pix Liquida may help treat alopecia areata.
February 2023 in “International Journal of Pharmaceutics” A new version of minoxidil, a hair loss treatment, was made using nanotechnology. This version, called minoxidil cubosomes, works better and causes fewer skin reactions than the old version. It also penetrates and stays in the skin better, promoting hair regrowth. It's safe and could be a good alternative to current treatments.
January 2022 in “Drugs of Today”
6 citations
,
September 2012 in “Clinical Interventions in Aging” Honokiol might help reduce male skin aging by maintaining testosterone levels.
October 2024 in “International Journal of Medical Arts” Corticosteroids regrow hair better and faster than pentoxifylline for alopecia areata.
6 citations
,
March 2003 in “Archiv Der Pharmazie” Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
4 citations
,
April 2018 in “Journal of Investigative Dermatology” Hydroxypinacolone retinoate is a potent anti-aging ingredient for skin that is more effective and less irritating than other forms of retinoids.
2 citations
,
October 2021 in “Clinical and experimental dermatology” Cyperus rotundus essential oil effectively treats underarm darkening, reduces inflammation, and slows hair growth.
Hair regrowth improved, but quality of life did not.
14 citations
,
April 2024 in “The Journal of Steroid Biochemistry and Molecular Biology” 5α-reductases increase epitestosterone's effect on androgen receptors.
June 2023 in “Italian journal of dermatology and venereology” The oral supplement improved hair loss in patients with telogen effluvium.
November 2021 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” The document does not give specific results for hair loss treatment effectiveness.
May 2026 in “Colloids and Surfaces B Biointerfaces”
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
March 2024 in “Journal of Neuroscience Research” Finasteride may reduce depression and anxiety in female rats and improve brain connectivity.
April 2025 in “International Journal of Pharmaceutics” Liposomes improve minoxidil delivery to hair follicles, enhancing treatment for hair loss.
October 2007 in “Inpharma Weekly”
January 1989 in “Journal of The American Academy of Dermatology” Dr. Jorizzo questions the long-term benefits of minoxidil and tretinoin, while Dr. Olsen defends their effectiveness and stresses the need for public education on these treatments.
4 citations
,
July 2020 in “Research Square (Research Square)” The research helps understand how finasteride works and aids drug development.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.